Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02384954
Title ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Altor Bioscience Corporation

chronic lymphocytic leukemia/small lymphocytic lymphoma

marginal zone B-cell lymphoma

lymphoplasmacytic lymphoma

follicular lymphoma


ALT-803 + Rituximab

Age Groups: adult
Covered Countries USA

No variant requirements are available.